Stock IOVA IOVANCE BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Real-time Estimate Cboe BZX
Other stock markets
 02:45:12 2024-05-28 pm EDT 		5-day change 1st Jan Change
9.765 USD -2.45% Intraday chart for Iovance Biotherapeutics, Inc. -5.38% +20.11%
May. 13 Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained MT
May. 13 Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
AQ
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
AQ
Iovance Biotherapeutics : 2022 Annual Report
PU
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AQ
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
AQ
Iovance Biotherapeutics: Q1 Earnings Snapshot
AQ
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
AQ
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
AQ
Iovance Biotherapeutics to Present at Upcoming Conferences
AQ
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - April 19, 2024
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AQ
Iovance Biotherapeutics to Present at Upcoming Conferences
AQ
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
AQ
Iovance Biotherapeutics to Present at Upcoming Conferences
AQ
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
AQ
Iovance Biotherapeutics: Q4 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IOVA Stock
  4. News Iovance Biotherapeutics, Inc.
  5. Press Releases